Next Disruptive Technology

Beyond technology and beyond medical, CRISPR DNA error correcting applications promise the most profound advancement in curing disease since the advent of molecular medicine. If you are looking for the next greatest thing, here it is. The three cutting edge equities carrying forward the research and early clinical trials, I call them the Three Amigos, already show double and triple fidget growth: Crispr Therapeutics, CRSP; Intellia Therapeutics, ITLA; and Editas Medicine, EDIT.